Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The work of the 2018 Nobel Prize Chemistry awardees is remarkable not only for its influence on modern biotech, but also for the rapidity with which it translated to commercial products.
The biotech community's decision to speak out in defense of freedom of the press is also a reaffirmation of core principles essential for the sector's success.
Despite spooking investors, new insights into DNA repair and the CRISPR gene-editing system are part and parcel of its progress from research tool to human therapy.
Addressing the commercial failure of the antibiotic market should be a priority for governments seeking to encourage development of new drugs against resistant bugs.
With a massive expansion in healthcare coverage, biotech's next big boom could occur in India. But this revolution will not be globalized—it will be about serving national needs.
Ultra-long read, single-molecule nanopore sequencers are beginning to find an expanding set of research applications in both human genomics and pathogenomics.
A new venture from Amazon, JP Morgans and Berkshire Hathaway has US healthcare in its crosshairs. It may also offer opportunities for innovators in health IT and digital medicine.
